Movatterモバイル変換

[0]ホーム
URL:

BRPI0908496A2 - angiogenesis inhibition - Google Patents

angiogenesis inhibition

Info

Publication number
BRPI0908496A2
BRPI0908496A2BRPI0908496ABRPI0908496ABRPI0908496A2BR PI0908496 A2BRPI0908496 A2BR PI0908496A2BR PI0908496 ABRPI0908496 ABR PI0908496ABR PI0908496 ABRPI0908496 ABR PI0908496ABR PI0908496 A2BRPI0908496 A2BR PI0908496A2
Authority
BR
Brazil
Prior art keywords
heavy chain
angiogenesis inhibition
vectors encoding
fusion proteins
igg heavy
Prior art date
Application number
BRPI0908496A
Other languages
Portuguese (pt)
Inventor
Scaria Abraham
Wadsworth Samuel
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme CorpfiledCriticalGenzyme Corp
Publication of BRPI0908496A2publicationCriticalpatent/BRPI0908496A2/en

Links

Classifications

Landscapes

Abstract

Translated fromPortuguese

inibição de angiogênese a presente invenção refere-se a proteínas de fusão compreendendo um polipeptídeo funcional, um ligante e uma molécula de cadeia pesada de lgg, e vetores codificando tais proteínas de fusão, que são fornecidas para inibir angiogenêse em indivíduos com condições patológicas relacionadas à neovascularização. particularmente, vetores codificando um antagonista vegf de fusão compreendendo um receptor de vegf fundido a uma molécula de cadeia pesada de lgg são fornecidos para tratar doenças oculares em um mamífero .Angiogenesis Inhibition The present invention relates to fusion proteins comprising a functional polypeptide, a ligand and an IgG heavy chain molecule, and vectors encoding such fusion proteins, which are provided to inhibit angiogenesis in individuals with pathological conditions related to neovascularization. particularly vectors encoding a fusion vegf antagonist comprising a vegf receptor fused to an Igg heavy chain molecule are provided to treat eye disease in a mammal.

BRPI0908496A2008-02-202009-02-20 angiogenesis inhibitionBRPI0908496A2 (en)

Applications Claiming Priority (4)

Application NumberPriority DateFiling DateTitle
US3007208P2008-02-202008-02-20
US3454608P2008-03-072008-03-07
US5663208P2008-05-282008-05-28
PCT/US2009/034709WO2009105669A2 (en)2008-02-202009-02-20Angiogenesis inhibition

Publications (1)

Publication NumberPublication Date
BRPI0908496A2true BRPI0908496A2 (en)2019-01-15

Family

ID=40986215

Family Applications (1)

Application NumberTitlePriority DateFiling Date
BRPI0908496ABRPI0908496A2 (en)2008-02-202009-02-20 angiogenesis inhibition

Country Status (5)

CountryLink
JP (1)JP2011512417A (en)
CN (1)CN101951925A (en)
BR (1)BRPI0908496A2 (en)
IL (1)IL207641A0 (en)
WO (1)WO2009105669A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
AU2012275133B2 (en)2011-06-302017-08-17Genzyme CorporationInhibitors of T-cell activation
TWI702955B (en)2012-05-152020-09-01澳大利亞商艾佛蘭屈澳洲私營有限公司Treatment of amd using aav sflt-1
HRP20221447T1 (en)*2013-03-132023-01-20Genzyme CorporationFusion proteins comprising pdgf and vegf binding portions and methods of using thereof
TWI687225B (en)*2014-02-062020-03-11美商健臻公司Compositions and methods for treating and preventing macular degeneration
SG10201810150UA (en)2014-03-172018-12-28Adverum Biotechnologies IncCompositions and methods for enhanced gene expression in cone cells
US9840553B2 (en)2014-06-282017-12-12Kodiak Sciences Inc.Dual PDGF/VEGF antagonists
WO2016005381A1 (en)*2014-07-102016-01-14Bayer Pharma AktiengesellschaftPdgfrbeta-fc fusion proteins and uses thereof
IL254148B (en)2015-03-022022-09-01Adverum Biotechnologies Inc Preparations and methods for intraocular delivery of polynucleotides to the retina
WO2016159652A1 (en)2015-03-312016-10-06일동제약주식회사Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
CA3005391A1 (en)*2015-11-192017-05-26Zhuhai Tairuishang Biopharm Ltd.Methods and compositions for binding vegf
GB2545763A (en)2015-12-232017-06-28Adverum Biotechnologies IncMutant viral capsid libraries and related systems and methods
BR112018013407A2 (en)2015-12-302018-12-18Kodiak Sciences Inc antibodies and conjugates thereof
KR101685532B1 (en)*2016-04-262016-12-13한국프라임제약주식회사A VEGFR fusion protein
JP2021514656A (en)2018-03-022021-06-17コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． IL-6 antibody and its fusion constructs and conjugates
GB201806333D0 (en)*2018-04-182018-05-30Glaxosmithkline Ip Dev LtdParvovirus vector production
CN108671229B (en)*2018-05-082022-03-25华博生物医药技术（上海）有限公司Pharmaceutical composition preparation of recombinant human vascular endothelial growth factor receptor-antibody fusion protein
US11912784B2 (en)2019-10-102024-02-27Kodiak Sciences Inc.Methods of treating an eye disorder
CN114181972A (en)*2021-11-232022-03-15上海本导基因技术有限公司Lentiviral vectors suitable for gene therapy of refractory angiogenic eye diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
NZ536274A (en)*2002-05-012008-04-30Univ FloridaImproved rAAV expression systems for genetic modification of specific capsid proteins
CN101094688B (en)*2004-09-132013-05-01建新公司Multimeric constructs

Also Published As

Publication numberPublication date
WO2009105669A3 (en)2009-12-17
CN101951925A (en)2011-01-19
WO2009105669A2 (en)2009-08-27
IL207641A0 (en)2010-12-30
JP2011512417A (en)2011-04-21

Similar Documents

PublicationPublication DateTitle
BRPI0908496A2 (en) angiogenesis inhibition
CO6400232A2 (en) HUMAN CGRP RECEPTORS LINK PROTEIN
CY1120144T1 (en) ANTI-N3PGLU BETA Peptide Amyloid Antibodies And Their Uses
PL3989972T3 (en) Glucagon-like peptide 1 receptor agonists
MA40882A (en) ANTIGEN BINDING MOLECULES INCLUDING ONE TRIMER OF TNF FAMILY LIGAND
MX387180B (en) FC REGION VARIANTS WITH NEONATAL FC RECEPTOR (FCRN) BINDING PROPERTIES.
PE20211272A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MY197854A (en)Antibodies against signal-regulatory protein alpha and methods of use
CY1120281T1 (en) TRAIL RECEPTORS IN SINGLE CHAIN PROTEINS
MX2015006548A (en)Binding proteins comprising at least two repeat domains against her2.
ECSP13013102A (en) UNIMMUNIZED DOMAINS THAT JOIN THE SERUM AND ITS USE TO EXTEND THE MIDDLE LIFE IN THE SERUM
BR112013028892A2 (en) modified biotin binding protein, fusion protein thereof and applications
EA201400568A1 (en) ALBUMINS CONNECTING ANTIBODIES AND THEIR CONNECTING FRAGMENTS
UY33983A (en) Union Proteins of the Antibody Type with Dual Variable Region that Have Orientation of the Union Region with Cross-linking.
BRPI0907363A2 (en) Methods and compositions for c-terminal element peptides and proteins
EP2152744A4 (en) PRION PROTEIN AS RECEPTOR FOR AMYLOID BETA OLIGOMERS
BR112014001573B8 (en) MULTIVALENT ANTIGEN FV MOLECULE
CL2007003771A1 (en) POLINUCLEOTIDE CODIFYING ANTIGEN OF N. MENINGITIDIS; VECTOR AND CELL GUESTS THAT UNDERSTAND IT; CODED POLYPEPTIDE; ANTIBODY THAT JOINS THE POLYPEPTIDE; COMPOSITION THAT INCLUDES THE POLINUCLEOTIDE, VECTOR, CELL, POLYPEPTIDE OR ANTIBODY AN
BRPI0915367B8 (en) anti-p2x7 peptide
BRPI0807480A2 (en) CONNECTING, IMMUNOGLOBULIN G, COMPOSITION AND FUSION PROTEIN
MX382848B (en) FC REGION VARIANTS WITH MODIFIED NEONATAL FC RECEPTOR (FCRN) BINDING AND MAINTAINED α-PROTEIN BINDING PROPERTIES.
EA201400488A1 (en) POLYPEPTIDE STRUCTURES AND THEIR APPLICATION
CL2014000737A1 (en) Dual function fusion protein comprising an agonist region of the glp-1 receptor and an agonist region of the fgf21 receptor.
DK2035447T3 (en) POLYPEPTIDE
DE602006020407D1 (en) PEPTIDES WITH NEUROPEPTIDE-2 RECEPTOR AGONIST ACTIVITY

Legal Events

DateCodeTitleDescription
B15IOthers concerning applications: loss of priority

Free format text:PERDA DAS PRIORIDADES US 61/030,072 , US 61/034,546 E US 61/056,632 REIVINDICADAS NO PCT/US2009/034709, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E ART 2O DA RESOLUCAO INPI 179 DE 21/02/2017. ESTA PERDA SE DEU PELO FATO DE O DEPOSITANTE CONSTANTE DA PETICAO DE REQUERIMENTO DO PEDIDO PCT (GENZYME CORPORATION) SER DISTINTO DAQUELES QUE DEPOSITARAM A PRIORIDADE REIVINDICADA E NAO APRESENTOU DOCUMENTO COMPROBATORIO DE CESSAO DENTRO DO PRAZO DE 60 DIAS A CONTAR DA DATA DA ENTRADA DA FASE NACIONAL, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 6O, E NO ART. 28 DA RESOLUCAO INPI-PR 77/2013.

B11ADismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11YDefinitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350Update of information on the portal [chapter 15.35 patent gazette]
[8]ページ先頭
©2009-2025 Movatter.jp